From the Journals

Psilocybin Trial in Treatment-Resistant Depression Shows Mixed Results

While primary endpoint results were negative, secondary measures showed greater reductions in depressive symptoms with high-dose psilocybin

Share

A phase 2b randomized clinical trial assessed the efficacy of psilocybin-assisted psychotherapy on treatment-resistant depression (TRD) but found no significant improvement in response rates at 6 weeks. The study involved 144 adults who had ceased antidepressant therapy. Participants received either 25 mg or 5 mg of psilocybin or a placebo (nicotinamide) combined with psychotherapy. Although primary endpoints were not met, higher doses showed early reductions in depressive symptoms. Methodological challenges, including functional unblinding and expectancy effects, complicate the interpretation of results, which need further research.

Original Source(s)

Psilocybin Trial in Treatment-Resistant Depression Shows Mixed Results

  • by Henry Thomas

  • March 20, 2026

Related Content

Can Biomarkers Refine Psych Dx?

Emerging evidence suggests biologic signals may predict treatment response and improve outcomes.

US Adolescent Sleep Loss Worsens Over 16 Years

Increase was driven largely by rising rates of very short sleep among high school students, with trends seen across demographic and behavioral groups.

Side Effects: Medicine's Blind Spot

Medicine is having a week: new insights on nutrition training, a rethink of “spring fatigue,” evidence that avocados may support artery health, and an AI that can spot rare hormone tumors from a hand photo